Tagitanlimab
Tagitanlimab (HBM-9167) is a humanized anti-PD-L1 antibody (IgG1κ type) . Tagitanlimab selectively blocks the interaction of PD-L1 and PD-1. Tagitanlimab has the potential to be studied in recurrent or metastatic nasopharyngeal carcinoma (NPC) [1][2].
Product Specifications
CAS Number
2417649-97-7
Product Name Alternative
HBM-9167; KL-A167
UNSPSC
12352203
Target
PD-1/PD-L1
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/tagitanlimab.html
Purity
99.0
Solubility
10 mM in DMSO
Smiles
[Tagitanlimab]
Molecular Weight
(144.95 kDa)
References & Citations
[1]Lu S, et al. Retrospect and Prospect for Lung Cancer in China: Clinical Advances of Immune Checkpoint Inhibitors. Oncologist. 2019 Feb;24 (Suppl 1) :S21-S30. |[2]Kaplon H, et al. Antibodies to watch in 2023. MAbs. 2023 Jan-Dec;15 (1) :2153410.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
MBS9004329 Inquire
Rabbit anti-Caenorhabditis elegans rab-18 Polyclonal Antibody
Sign In for Pricing
View Details